L. Bière

Pembrolizumab plus anthracyclines in triple-negative breast cancer: prospective evaluation of early cardiac safety

Biomarker elevations were common but rarely translated into functional cardiac impairment, supporting the short-term cardiac safety of pembrolizumab when managed within a structured cardio-oncology surveillance program.